| Programs | Indications | Preclinical | IND Enabling Activities | Phase 1 | Phase 2 | Global Rights |
|---|---|---|---|---|---|---|
| CB4211 | NASH |
Preclinical Phase complete
|
IND Enabling Activities Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
 |
| Obesity |
Preclinical Phase complete
|
IND Enabling Activities Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
|
|
| CB5138-3 | IPF, Fibrotic Diseases |
Preclinical Phase complete
|
IND Enabling Activities Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
|
| Apelin Agonists | Covid-19 ARDS, ARDS |
Preclinical Phase in progress
|
IND Enabling Activities Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
|
| Discovery Efforts | Fibrotic, Inflammatory, etc. |
Preclinical Phase in progress
|
IND Enabling Activities Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
|
CB5138-3 for Idiopathic Pulmonary Fibrosis and Other Fibrotic Diseases
Anti-fibrotic & Anti-inflammatory
Our second clinical candidate.
View Program
CB4211 for Nonalcoholic Steatohepatitis (NASH) and Obesity
Novel Mechanism of Action: Enhances Insulin Signaling
The first analog from our Mito+ platform to be tested in humans.
View Program
CB5064 Analogs for Acute Respiratory Distress Syndrome (ARDS)
Selectively Activates the Apelin Receptor
View ProgramDiscovery Efforts
Continued mining of the mitochondrial genome and development of novel analogs
View ProgramPosters & White Papers
View our posters and white papers regarding our research and science.
View Publications